Anonymous
Guest
Anonymous
Guest
Yes, Lilly has yet to make a dollar from it's purchase of Avid. But I believe the upfront purchase price was only $300M, with up to an additional $500M of milestone payments, contingent on sales of the amyloid imaging agent.
In contrast, they blew $6 Billion on Imclone, and all they have to show for it is about $300 million a year in Erbitux revenue and a few mABs in development that are of very questionable value.
Sure but those LCC accounting tricks miss the "maintenance" and "lost opportunity costs" of the Imclone purchase. But, as we know the whole company is a MASSIVE TAX WRITE OFF and yet we complain about regulation. It's a big joke.
You want to be recognized as a "health care company" then at least REMOTELY try to resemble one... every single move this company makes is money money money money.
"Momma don't send me down to rob that bank again I got a notion you're leading me to sin"
Google it.